熱門資訊> 正文
Emergent Bio在融资交易后下滑
2024-09-04 03:08
- Shares of Emergent BioSolutions (NYSE:EBS) fell sharply on Tuesday after the Maryland-based biotech announced a new credit facility agreement with Oak Hill Advisors to secure a term loan worth up to $250M.
- In connection with the deal, the company has agreed to provide lenders with $10M worth of shares of its common stock at a price equal to the 30-day volume-weighted average price per share.
- Emergent (EBS) has also issued warrants allowing lenders to purchase 2.5M shares of its common stock at a premium to VWAP.
- The five-year term loan facility extends through 2029. The company intends to use some of its proceeds to repay the outstanding amounts under a previous senior-term loan facility, and expects the remainder to help strengthen its balance sheet.
More on Emergent Biosolutions
- Mpox Stocks Have Popped, But Pickings Are Slim For The Discerning Investor
- Emergent BioSolutions: Speculative Buy Amid Potential Monkeypox Vaccine Approval
- Emergent BioSolutions Inc. (EBS) Q2 2024 Earnings Call Transcript
- UNICEF issues emergency tender to secure mpox vaccines
- Emergent stock jumps as FDA clears smallpox vaccine for people at high risk of mpox
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
